Cargando…
Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts
BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048948/ https://www.ncbi.nlm.nih.gov/pubmed/32158645 http://dx.doi.org/10.2147/VMRR.S236912 |
_version_ | 1783502370317008896 |
---|---|
author | Kiss, István Kovács, Edit Zádori, Zoltán Mészáros, István Cságola, Attila Bajnóczi, Pál Mortensen, Preben Palya, Vilmos |
author_facet | Kiss, István Kovács, Edit Zádori, Zoltán Mészáros, István Cságola, Attila Bajnóczi, Pál Mortensen, Preben Palya, Vilmos |
author_sort | Kiss, István |
collection | PubMed |
description | BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared. RESULTS: The K22 vaccine strain of Parvoruvax(®) (PVX) was characterized as “Kresse-like” based on the epitope mapping data. Vaccination of the gilts induced a low level of antibody responses. Based on foetal mortality, the number of sows which had challenge virus-affected foetuses, the percent of PPV positive piglets/litters plus their PPV genome and viral load PVX outscored the other vaccinated groups. CONCLUSION: Stronger protection was provided by the “Kresse-like” K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection. |
format | Online Article Text |
id | pubmed-7048948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70489482020-03-10 Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts Kiss, István Kovács, Edit Zádori, Zoltán Mészáros, István Cságola, Attila Bajnóczi, Pál Mortensen, Preben Palya, Vilmos Vet Med (Auckl) Original Research BACKGROUND/INTRODUCTION: Porcine parvovirus (PPV), the causative agent of severe reproductive failures in pigs, is present worldwide. The witnessed spread of the virulent 27a type PPV strains since its recognition raised concerns about the efficacy of the available commercial vaccines. METHODS: To address this question, vaccinated pregnant gilts were challenged with a PPV-27a-like virus strain and parameters related to vaccine efficacy were compared. RESULTS: The K22 vaccine strain of Parvoruvax(®) (PVX) was characterized as “Kresse-like” based on the epitope mapping data. Vaccination of the gilts induced a low level of antibody responses. Based on foetal mortality, the number of sows which had challenge virus-affected foetuses, the percent of PPV positive piglets/litters plus their PPV genome and viral load PVX outscored the other vaccinated groups. CONCLUSION: Stronger protection was provided by the “Kresse-like” K22 PPV strain-based vaccine than by the NADL-2 and NADL-like strain-based commercial vaccines against a PPV-27a cluster strain challenge. Vaccine-induced antibody levels as measured pre-challenge were not found to be an accurate indicator of protection. Dove 2020-02-24 /pmc/articles/PMC7048948/ /pubmed/32158645 http://dx.doi.org/10.2147/VMRR.S236912 Text en © 2020 Kiss et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kiss, István Kovács, Edit Zádori, Zoltán Mészáros, István Cságola, Attila Bajnóczi, Pál Mortensen, Preben Palya, Vilmos Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title | Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title_full | Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title_fullStr | Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title_full_unstemmed | Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title_short | Vaccine Protection Against Experimental Challenge Infection with a PPV-27a Genotype Virus in Pregnant Gilts |
title_sort | vaccine protection against experimental challenge infection with a ppv-27a genotype virus in pregnant gilts |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048948/ https://www.ncbi.nlm.nih.gov/pubmed/32158645 http://dx.doi.org/10.2147/VMRR.S236912 |
work_keys_str_mv | AT kissistvan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT kovacsedit vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT zadorizoltan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT meszarosistvan vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT csagolaattila vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT bajnoczipal vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT mortensenpreben vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts AT palyavilmos vaccineprotectionagainstexperimentalchallengeinfectionwithappv27agenotypevirusinpregnantgilts |